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eling and spine atrophy and loss in the rat hippocampus trig-
gering Tau missorting at hippocampal synapses with the 
participation of specific phosphorylated Tau isoforms in this 
 synaptic accumulation.  Key Messages: The above findings 
suggest that Tau plays an essential role in mediating the 
neurodegenerative effects of stress and GCs towards the de-
velopment of AD pathology. In addition, they highlight the 
involvement of Tau missorting in mechanism(s) of synaptic 
atrophy, beyond AD adding to our limited knowledge of the 
mechanisms through which stress causes brain pathology. 
 © 2015 S. Karger AG, Basel 
 Tau Protein in and beyond Alzheimer’s Disease 
 Improvements in life span over the last decades have, 
unfortunately, not been matched by improvements in the 
mental health span. The World Health Organization esti-
mates that a leading cause of mental disability in the com-
ing years will be Alzheimer’s disease (AD), a disease that 
already affects more than 35 million people worldwide. To 
combat this brain disorder, clinical and basic research 
continues to strive to improve the mechanistic under-
standing of AD pathology which is characterized by: (i) 
the overproduction of amyloid-β (Aβ), a neurotoxic pep-
tide which fibrillates and accumulates as senile plaques in 
the brain, and (ii) hyperphosphorylation of the cytoskel-
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 Abstract 
 Background: Alzheimer’s disease (AD) is a multifactorial 
neurodegenerative disorder with a complex physiopathol-
ogy and still undefined initiators. Several risk factors have 
been suggested for AD with recent evidence supporting an 
etiopathogenic role of chronic environmental stress and glu-
cocorticoids (GCs, stress hormones) in the development of 
the disease. Indeed, both AD and chronic stress are associ-
ated with neuronal atrophy, synaptic loss and cognitive im-
pairment. Our previous studies have demonstrated the ag-
gravating role of stress and GCs on AD pathology, including 
Tau hyperphosphorylation and aggregation and cognitive 
deficits in various AD models. In light of the suggested in-
volvement of Tau missorting in AD synaptotoxity and the 
dual cytoplasmic and synaptic role of Tau, our recent studies 
focused on the possible role of Tau in the underlying cas-
cades of stress/GC neuronal malfunction/atrophy in wild-
type animals by monitoring the intracellular localization of 
Tau and its phosphorylation status in different cellular com-
partments.  Summary: Biochemical, ultrastructural, behav-
ioral and neurostructural analysis have helped demonstrate 
that prolonged GC administration leads to dendritic remod-
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etal protein Tau which accumulates in neuronal soma as 
insoluble aggregates and neurofibrillary tangles  [1, 2] . Se-
quential cleavage of the transmembrane protein amyloid 
precursor protein by β- and γ-secretases yields Aβ; this 
cellular pathway is called amyloid precursor protein (APP) 
misprocessing. Numerous studies have causally linked Aβ 
to synaptic malfunction, neuronal atrophy and synaptic 
loss. In addition, it has been suggested that Aβ also triggers 
the other neurodegenerative mechanism of AD, the ab-
normal Tau hyperphosphorylation, leading to the forma-
tion of Tau aggregates and neuronal atrophy and loss.
 The potential key role played of Tau in AD gained rec-
ognition relatively recently, and the protein is now a tar-
get in several drug discovery programs aimed at AD  [3] . 
There is now strong evidence that Tau mediates at least 
some of the neuro- and synaptotoxic effects of Aβ  [4–7] . 
Accordingly, our own and other work has demonstrated 
that synaptic dysfunction and atrophy as well as memory 
impairments are accompanied by the accumulation of 
hyperphosphorylated Tau in synapses, implicating hy-
perphosphorylated tau in AD synaptic loss  [8–10] . Inter-
estingly, while it is generally known as an axonal protein 
with a role in microtubule stabilization and assembly, Tau 
was recently shown to be present at synapses where it acts 
as scaffold protein and interacts with various proteins/
receptors that modulate synaptic signaling and plasticity 
 [11, 12] ; still, the exact role of Tau at synapses needs fur-
ther investigation. 
 Increasingly, Tau is being recognized to play a key role 
in brain physiology and pathology that goes beyond AD. 
For example, Tau has been suggested to be an essential 
mediator of different neuropathological processes be-
yond AD, e.g. excitotoxicity and epileptogenesis; hereby, 
Tau depletion blocks the neuronal malfunction damage 
and behavioral deficits  [13–15] . Further, our previous 
work indicated that Tau may lie at the core of chronic 
stress-induced pathological aging of the brain  [10, 16] . 
Those findings proposed that Tau hyperphosphorylation 
may be a critical mechanism through which chronic stress 
and glucocorticoids (GCs, stress hormones) initiate neu-
ropathological events that precipitate AD pathology  [17] . 
Together, the above findings highlight Tau as a potential 
key modulator of neuronal and synaptic function during 
healthy and pathological brain states. 
 Chronic Stress and GCs as Precipitators of AD 
Pathology 
 Several factors that place individuals at risk for devel-
oping AD have been identified. Clinical evidence sup-
ports an etiopathogenic role for chronic stress and elevat-
ed GC levels in the development of AD pathology (fig. 1). 
Human studies suggest that exposure to chronic stress 
advances the onset of familial AD  [18, 19] while high lev-
els of GCs have been reported in the blood plasma, saliva 
and cerebrospinal fluid of AD patients  [20–24] ; the in-
creased GC levels commonly associate with memory def-
icits in these patients  [25, 26] . Since chronic elevation of 
GC levels is known to impair memory and other cognitive 
functions, it appears likely that GCs contribute to the pro-
gressive cognitive decline observed in AD. The hippo-
campus is a principal target of GC actions, and hippo-
campal neurons express the highest levels of GC receptors 
in the brain. The hippocampus is early affected in AD, 
and its dysfunction results in impairments in declarative, 
spatial and contextual memory. These facts, together with 
the important part played by the hippocampus in re-
straining GC secretion and, thus, regulating physiological 
mechanisms of stress response, have made this brain re-
gion a focus of research fields of both stress and AD rais-
ing the question of how high GC levels and chronic stress 
 Fig. 1. The neurodegenerative potential of 
chronic stress and GCs may be mediated 
through Tau protein. Prolonged exposure 
to GCs and/or stress triggers the aberrant 
hyperphosphorylation of the cytoskeletal 
protein Tau (p-Tau; mainly localized in ax-
ons; red in the healthy neuron), through the 
activation of different kinases (e.g. GSK3-β 
and cdk5). This leads to the somatodendrit-
ic accumulation as well as synaptic missort-
ing of Tau (red in diseased neuron), leading 
to neuronal malfunction and synaptic loss 
as well as cognitive impairment. 
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impact the deterioration of hippocampal functions relat-
ed to toxic Aβ and Tau hyperphosphorylation.
 Previous studies from our own and other laboratories 
showed that exposure to chronic stress or prolonged 
treatment with the synthetic GC dexamethasone result in 
increased APP misprocessing and Aβ production in the 
hippocampus of AD animal models in parallel with mem-
ory deficits  [27–29] . Further, we and others have shown 
that chronic stress and/or GC treatment trigger Tau hy-
perphosphorylation in neuronal somata in various ani-
mal models of AD; notably, these treatments hyperphos-
phorylated several Tau epitopes  [10, 27] known to be as-
sociated with cytoskeletal pathology, synaptic loss and 
hippocampal atrophy as well as impairments of memory, 
speed of mental processing, and executive functions in 
AD patients (e.g. pSer262, pThr231)  [30–35] . Our own 
work also demonstrated that GC treatment and chronic 
stress increased Tau accumulation by affecting turnover 
of the protein  [10, 16] , indicating that GCs may reduce 
Tau degradation through dysregulation of molecular 
chaperones responsible for tau proteostasis (e.g. heat-
shock proteins Hsp90 and Hsp70)  [36] . Interestingly, 
Hsp90 and Hsp70 serve to maintain GC receptors in a 
high-affinity state, thus suggesting a point at which GC/
GC receptor signaling and Tau degradation machinery 
can intersect. The reduced Tau degradation could also 
facilitate the increased aggregation of Tau into insoluble 
forms triggered by stress in P301L-Tau Tg mice (mice ex-
pressing human tau carrying the most common Tau mu-
tation P301L)  [36] . In this last study, chronic stress was 
shown to promote C-terminal truncation of Tau by cas-
pase-3 and abnormal conformation of Tau in the hip-
pocampus of P301L-Tau Tg mice. Together with Tau hy-
perphosphorylation, both truncation and abnormal con-
formation of tau precede its aggregation and formation
of neurofibrillary tangles  [37–39] , thus serving as early 
markers of disease. 
 Tau Accumulation: Linking Stress with Synaptic 
Pathology and AD? 
 Recent human and animal studies suggest that mislo-
cated Tau, due to missorting in dendritic spines and syn-
apses, underpins the synaptic pathology found in AD  [8, 
40–42] . This could possibly explain the known correla-
tion between Tau hyperphosphorylation and synaptic 
loss and memory impairment in experimental animals  [9, 
40] , and such a mechanism could also possibly explain 
how stress results in synapse and memory loss. These hy-
potheses are indeed supported by very new studies in our 
laboratory that implicate Tau missorting in GC-triggered 
hippocampal pathology in wild-type animals  [43] . We 
demonstrated, both by biochemical (subcellular fraction-
ation) and ultrastructural (electron microscope) analysis, 
that prolonged GC administration in wild-type animals 
led to cytosolic and dendritic Tau accumulation in the rat 
hippocampus and triggered Tau hyperphosphorylation 
in epitopes related to its malfunction (Ser396/404) and 
cytoskeletal pathology (e.g. Thr231 and Ser262). In addi-
tion, we show that chronic GC administration also in-
creased Tau levels in the synaptic compartment related to 
dendritic remodeling and synaptic loss exhibiting a pref-
erential subcellular accumulation of different Tau iso-
forms in different intracellular compartments  [43] . Over-
all, these recent findings from our laboratory support a 
role for Tau and its missorting in GC-induced dendritic 
remodeling and synaptic loss. 
 This brief review highlights the essential role of Tau 
protein in the neurodegenerative potential of chronic 
stress and GC towards the development of AD. It also 
summarizes the emerging evidence that Tau missorting 
may be a common mechanism in both AD and stress-
related disorders of the brain adding to our knowledge 
about the poorly understood cellular cascades of stress-
related brain pathology.
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